SONN
Income statement / Annual
Last year (2024), Sonnet BioTherapeutics Holdings, Inc.'s total revenue was $18,626.00,
a decrease of 87.40% from the previous year.
In 2024, Sonnet BioTherapeutics Holdings, Inc.'s net income was -$7.44 M.
See Sonnet BioTherapeutics Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$18,626.00
|
$147,805.00
|
$349,943.00
|
$483,626.00
|
$0.00
|
$40.61 M
|
$30.73 M
|
$41.43 M
|
$41.70 M
|
$42.40 M
|
| Cost of Revenue |
$0.00 |
$11.81 M |
$93,257.00 |
$16.63 M |
$58,313.00 |
$7.93 M |
$29.94 M |
$39.41 M |
$38.38 M |
$14.04 M |
| Gross Profit |
$18,626.00 |
-$11.67 M |
$256,686.00 |
-$16.15 M |
-$58,313.00 |
$32.68 M |
$791,106.00 |
$2.03 M |
$3.33 M |
$28.36 M |
| Gross Profit Ratio |
1 |
-78.93 |
0.73 |
-33.4 |
0 |
0.8 |
0.03 |
0.05 |
0.08 |
0.67 |
| Research and Development
Expenses |
$5.74 M
|
$11.81 M
|
$21.44 M
|
$16.63 M
|
$9.88 M
|
$2.20 M
|
$154,717.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$6.13 M
|
$7.13 M
|
$8.58 M
|
$8.94 M
|
$7.53 M
|
$2.51 M
|
$363,877.00
|
$4.55 M
|
$5.80 M
|
$7.42 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.50 M
|
$0.00
|
$145,130.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.13 M
|
$7.13 M
|
$8.58 M
|
$8.94 M
|
$7.53 M
|
$2.51 M
|
$3.86 M
|
$4.55 M
|
$5.95 M
|
$7.42 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$125,501.00 |
$0.00 |
$11.05 M |
$11.05 M |
$5.19 M |
$3.45 M |
$3.36 M |
| Operating Expenses |
$11.87 M |
$18.94 M |
$30.02 M |
$25.57 M |
$17.41 M |
$4.71 M |
$3.86 M |
$4.55 M |
$5.95 M |
$10.78 M |
| Cost And Expenses |
$11.87 M |
$18.94 M |
$30.02 M |
$25.57 M |
$17.41 M |
$4.71 M |
$33.80 M |
$43.95 M |
$44.32 M |
$24.82 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$15.00 |
$20,677.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$20,677.00 |
$162,873.00 |
$381,676.00 |
-$2.59 M |
-$2.35 M |
-$3.47 M |
| Depreciation &
Amortization |
$0.00
|
$75,750.00
|
$93,257.00
|
$95,162.00
|
$58,313.00
|
$3.54 M
|
$1.82 M
|
$2.28 M
|
$2.34 M
|
$2.36 M
|
| EBITDA |
-$11.85 M
|
-$18.72 M
|
-$29.58 M
|
-$24.99 M
|
-$24.24 M
|
-$13.15 M
|
-$3.71 M
|
-$2.93 M
|
$541,147.00
|
-$2.73 M
|
| EBITDA Ratio |
-636.18 |
-126.63 |
-84.63 |
-51.63 |
0 |
-0.12 |
-0.04 |
-0.01 |
-0.01 |
-0.32 |
| Operating Income Ratio
|
-636.18
|
-127.14
|
-84.78
|
-51.87
|
0
|
-0.12
|
-0.1
|
-0.06
|
-0.06
|
-0.27
|
| Total Other
Income/Expenses Net |
$4.41 M
|
-$40,077.00
|
-$52,482.00
|
$103,475.00
|
-$27,343.00
|
-$162,873.00
|
-$7.38 M
|
-$5.29 M
|
-$1.53 M
|
$3.59 M
|
| Income Before Tax |
-$7.44 M |
-$18.83 M |
-$29.72 M |
-$24.98 M |
-$24.27 M |
-$4.87 M |
-$8.07 M |
-$7.81 M |
-$4.15 M |
-$14.32 M |
| Income Before Tax Ratio
|
-399.29
|
-127.42
|
-84.93
|
-51.66
|
0
|
-0.12
|
-0.26
|
-0.19
|
-0.1
|
-0.34
|
| Income Tax Expense |
$0.00 |
$0.00 |
$52,482.00 |
$22,026.00 |
$6.80 M |
$162,873.00 |
-$701,224.00 |
-$644,429.00 |
$198,463.00 |
-$187,568.00 |
| Net Income |
-$7.44 M |
-$18.83 M |
-$29.77 M |
-$25.01 M |
-$31.06 M |
-$5.03 M |
-$6.85 M |
-$6.79 M |
-$9.08 M |
-$12.14 M |
| Net Income Ratio |
-399.29 |
-127.42 |
-85.08 |
-51.71 |
0 |
-0.12 |
-0.22 |
-0.16 |
-0.22 |
-0.29 |
| EPS |
-11.35 |
-18.14 |
-150.79 |
-313.76 |
-1015.55 |
-5776.45 |
-15593.25 |
-21549.2 |
-33503.15 |
-42597.94 |
| EPS Diluted |
-11.35 |
-18.14 |
-150.79 |
-313.76 |
-1015.55 |
-5776.45 |
-15593.25 |
-21549.2 |
-33503.15 |
-42597.94 |
| Weighted Average Shares
Out |
$655,240.00
|
$1.04 M
|
$197,462.00
|
$79,699.00
|
$30,585.00
|
$871.48
|
$439.58
|
$315.31
|
$270.92
|
$284.91
|
| Weighted Average Shares
Out Diluted |
$655,240.00
|
$1.04 M
|
$197,462.00
|
$79,699.00
|
$30,585.00
|
$871.48
|
$439.58
|
$315.31
|
$270.92
|
$284.91
|
| Link |
|
|
|
|
|
|
|
|
|
|
